ライフサイエンスコーパス: ductal carcinoma in situ

1 ast cancer (invasive cancers or non-invasive ductal carcinoma in situ).

2 the kinase domain and overexpressed only in ductal carcinoma in situ.

3 One (4%) of the 23 patients had ductal carcinoma in situ.

4 till developed mammary gland hyperplasia and ductal carcinoma in situ.

5 during the transition from pre-malignancy to ductal carcinoma in situ.

6 ent stromal angiogenesis that resemble human ductal carcinoma in situ.

7 o MR imaging sensitivity in the detection of ductal carcinoma in situ.

8 s, including atypical ductal hyperplasia and ductal carcinoma in situ.

9 asive tumors than in normal breast tissue or ductal carcinoma in situ.

10 of 2.82 (1.72-4.63) and 1.56 (1.38-1.75) for ductal carcinoma in situ.

11 Most tumours are ductal and 10% are ductal carcinoma in situ.

12 progression from usual ductal hyperplasia to ductal carcinoma in situ.

13 s, 129 (75%) were invasive and 43 (25%) were ductal carcinoma in situ.

14 cinoma compared with normal breast tissue or ductal carcinoma in situ.

15 nvasive cancer; one had extensive multifocal ductal carcinoma in situ.

16 obular units microdissected from 20 cases of ductal carcinoma in situ.

17 rom surgery for invasive breast carcinoma or ductal carcinoma in situ.

18 ncers detected at screening mammography were ductal carcinoma in situ.

19 mphovascular invasion and intermediate grade ductal carcinoma in situ.

20 from having a choice of effective agents for ductal carcinoma in situ.

21 al growth factor receptor 2, with associated ductal carcinoma in situ.

22 he management of both low-risk and high-risk ductal carcinoma in situ.

23 reast cancer in postmenopausal patients with ductal carcinoma in situ.

24 r widespread low-grade or intermediate-grade ductal carcinoma in situ.

25 nifested as calcifications and 28 (65%) were ductal carcinoma in situ.

26 nd 1.0 cm (range, 0 to 9.3) in patients with ductal carcinoma in situ.

27 edge of the specimen removed in the case of ductal carcinoma in situ.

28 e group of stakeholders on the management of ductal carcinoma in situ.

29 Average tumor size was 2.8 cm for ductal carcinoma in situ (0.05-17.0 cm), 2.4 cm for inva

30 e (0.45 [0.24-0.85]; p=0.01) and ipsilateral ductal carcinoma in situ (0.36 [0.19-0.66]; p=0.0004), b

31 r (HR 0.66 [95% CI 0.54-0.81], p<0.0001) and ductal carcinoma in situ (0.65 [0.43-1.00], p=0.05), but

32 normal mammary glands (10 of 10) but not all ductal carcinoma in situ [11 of 19 (57.9%), P = 0.018] a

33 who were screened, eight were diagnosed with ductal carcinoma in situ, 16 with early stage disease (1

34 Ductal carcinoma in situ (21 of 87 lesions [24%]; 95% CI

35 12% bilateral), with no dominant histology (ductal carcinoma in situ, 35%; infiltrating ductal carci

36 A computer simulation is used to model ductal carcinoma in situ, a form of non-invasive breast

37 are associated with malignant progression of ductal carcinoma in situ, a precancerous lesion.

38 ive, close or positive for invasive tumor or ductal carcinoma in situ according to central pathology

39 Invasive ductal carcinoma and ductal carcinoma in situ account for about 85% of breast

40 fferent for invasive carcinoma compared with ductal carcinoma-in-situ (all P > or =.27).

41 de glioma, and 2 preinvasive breast cancers [ductal carcinoma in situ]); all but 1 required only rese

42 alateral breast cancer, invasive disease, or ductal carcinoma in situ), analysed by intention to trea

43 of breast cancer (invasive breast cancer and ductal carcinoma in situ), analysed by intention to trea

44 Detected cancers with change were 21.1% ductal carcinoma in situ and 78.9% invasive carcinoma.

45 Detected cancers with no change were 19.3% ductal carcinoma in situ and 80.7% invasive carcinoma.

46 but is significantly reduced in precancerous ductal carcinoma in situ and all breast cancer subtypes.

47 detected at similar frequencies during early ductal carcinoma in situ and in the later invasive ducta

48 s associated with COX-2 expression levels in ductal carcinoma in situ and invasive cancer.

49 ductal epithelium, usual ductal hyperplasia, ductal carcinoma in situ and invasive cancer.

50 samples were separated from most noninvasive ductal carcinoma in situ and invasive carcinomas by incr

51 gnancy, specifically a 3.3 relative risk for ductal carcinoma in situ and invasive ductal carcinoma,

52 the incidence of early-stage breast cancer (ductal carcinoma in situ and localized disease) and late

53 e and metastatic breast cancer compared with ductal carcinoma in situ and nonmalignant breast, and ce

54 h tumor progression, with high expression in ductal carcinoma in situ and reduced expression in invas

55 re pooled separately from five patients with ductal carcinoma in situ and separately from five patien

56 All women with ductal carcinoma-in-situ and a 20% random sample of wome

57 c analysis resulted in the diagnosis of four ductal carcinomas in situ and 10 invasive carcinomas (fi

58 cancers were diagnosed in 18 patients (nine ductal carcinomas in situ and 11 invasive breast cancers

59 Eleven breast cancers (four ductal carcinomas in situ and seven invasive cancers; al

60 s; 30 (20%) proved malignant and included 27 ductal carcinomas in situ and three low-grade invasive a

61 tive risk (RR) of breast cancer (invasive or ductal carcinoma-in-situ) and type of breast cancer with

62 ents (23%) had invasive cancer, 45 (19%) had ductal carcinoma in situ, and 125 (53%) had both; 11 pat

63 psies from invasive ductal carcinoma, 8 from ductal carcinoma in situ, and 6 from normal breast.

64 inomas: an infiltrating lobular carcinoma, a ductal carcinoma in situ, and an infiltrating tubular ca

65 inoma compared to normal breast epithelia or ductal carcinoma in situ, and general loss of Nuc-pYStat

66 cimens from reduction mammoplasty, adenosis, ductal carcinoma in situ, and infiltrating ductal carcin

67 solated tissues from patient-matched normal, ductal carcinoma in situ, and invasive ductal carcinoma

68 TA1s-TG mice revealed ductal hyperplasia and ductal carcinoma in situ, and low incidence of palpable

69 Ten (34%) cancers were ductal carcinoma in situ, and the remaining cancers had

70 Indolent non-progressive forms of ductal carcinoma in situ are managed according to simila

71 sitive margins (ink on invasive carcinoma or ductal carcinoma in situ) are associated with a two-fold

72 ordant biopsy findings, two were upgraded to ductal carcinoma in situ at surgery (n = 5); none of the

73 patients with node-negative breast cancer or ductal carcinoma in situ before final treatment is recom

74 nd progressed through ductal hyperplasia and ductal carcinoma in situ before invasive cancer.

75 nual incidence of invasive plus noninvasive (ductal carcinoma in situ) breast cancers was 0.35% on ex

76 ibrocystic changes, atypical hyperplasia, or ductal carcinoma in situ, but was expressed in 36 of 118

77 d the number of intraductal hyperplasias and ductal carcinomas in situ by 50 days of age in Wistar-Fu

78 ge, menopausal status, presence of extensive ductal carcinoma in situ, clinical tumour size, nodal st

79 erinterpreted and 8.6% underinterpreted) and ductal carcinoma in situ (DCIS) (18.5% overinterpreted a

80 Young age (P < .001) and presence of ductal carcinoma in situ (DCIS) (HR, 2.15; 95% CI, 1.36-

81 (ILC) (P < .001) and 21 of 38 (55%) cases of ductal carcinoma in situ (DCIS) (P < .01).

82 scribe the progression through the grades of ductal carcinoma in situ (DCIS) 1, 2, and 3, and through

83 Ductal carcinoma in situ (DCIS) accounts for 20% of all

84 To determine whether residual ductal carcinoma in situ (DCIS) after completion of preo

85 fit with adjuvant tamoxifen in patients with ductal carcinoma in situ (DCIS) after lumpectomy and rad

86 therapy (RT) after a local excision (LE) for ductal carcinoma in situ (DCIS) aims at reduction of the

87 04 malignant index lesions, of which 63 were ductal carcinoma in situ (DCIS) and 341 were invasive ca

88 atients with breast cancer [15 patients with ductal carcinoma in situ (DCIS) and 75 patients with IDC

89 with increased risk of recurrent disease in ductal carcinoma in situ (DCIS) and a poorer prognosis i

90 Immunohistochemical (IHC) analysis of ductal carcinoma in situ (DCIS) and IDC showed that the

91 1 expression reduced in approximately 50% of ductal carcinoma in situ (DCIS) and invasive breast canc

92 perplasia (ADH), are candidate precursors to ductal carcinoma in situ (DCIS) and invasive cancer.

93 ity (CIN) is a defining trait of early human ductal carcinoma in situ (DCIS) and is believed to preci

94 lecular events required for the formation of ductal carcinoma in situ (DCIS) and its progression to i

95 stigate, in a large population of women with ductal carcinoma in situ (DCIS) and long follow-up, the

96 that investigates progression of early-stage ductal carcinoma in situ (DCIS) and report that compromi

97 nonpalpable invasive breast cancer (IBC) or ductal carcinoma in situ (DCIS) and to examine whether t

98 (and breast cancer cell lines) and adjacent ductal carcinoma in situ (DCIS) as well as its associati

99 ion of atypical ductal hyperplasia (ADH) and ductal carcinoma in situ (DCIS) at magnetic resonance (M

100 surgery (BCS) is an effective treatment for ductal carcinoma in situ (DCIS) but women who undergo BC

101 l hyperplasia (DH), lobular hyperplasia, and ductal carcinoma in situ (DCIS) by 4 months of age.

102 s) after breast-conserving surgery (BCS) for ductal carcinoma in situ (DCIS) by approximately 50% aft

103 A subset of ductal carcinoma in situ (DCIS) cases were also found to

104 ew breast events of ipsilateral invasive and ductal carcinoma in situ (DCIS) compared with no radioth

105 st ultrasonography) in the identification of ductal carcinoma in situ (DCIS) components of biopsy-pro

106 Ductal carcinoma in situ (DCIS) constitutes a major publ

107 Previously, we found that basal-like ductal carcinoma in situ (DCIS) contains cancer stem-lik

108 on of the overdiagnosis and overtreatment of ductal carcinoma in situ (DCIS) detected by mammography

109 The prevalence of ductal carcinoma in situ (DCIS) diagnoses has significan

110 rmal breast/invasive ductal breast carcinoma/ductal carcinoma in situ (DCIS) from breast cancer patie

111 nd in earlier detection of breast cancer and ductal carcinoma in situ (DCIS) in a transgenic mouse mo

112 Seven patients (3.8%) had malignant results: ductal carcinoma in situ (DCIS) in four, invasive ductal

113 [64%] vs 349 of 845 [41%], P < .0001), have ductal carcinoma in situ (DCIS) in the index breast (31%

114 in eight, and well-differentiated papillary ductal carcinoma in situ (DCIS) in two.

115 atient-derived epithelial cells derived from ductal carcinoma in situ (DCIS) increased secretion of t

116 markers, and clinical outcome indicate that ductal carcinoma in situ (DCIS) is a heterogeneous disea

117 Ductal carcinoma in situ (DCIS) is a heterogeneous group

118 e value of screen detection and treatment of ductal carcinoma in situ (DCIS) is a matter of controver

119 Ductal carcinoma in situ (DCIS) is a noninvasive precurs

120 Ductal carcinoma in situ (DCIS) is a precursor lesion of

121 Ductal carcinoma in situ (DCIS) is a subtype of breast c

122 Breast ductal carcinoma in situ (DCIS) is being found in great

123 Ductal carcinoma in situ (DCIS) is characterized by duct

124 Ductal carcinoma in situ (DCIS) is defined as a prolifer

125 e tumor bed after whole-breast RT (WBRT) for ductal carcinoma in situ (DCIS) is largely extrapolated

126 While the mortality associated with ductal carcinoma in situ (DCIS) is minimal, the risk of

127 Ductal carcinoma in situ (DCIS) is the fourth leading ca

128 orrelates with HER2-positive status in human ductal carcinoma in situ (DCIS) lesions and invasive bre

129 etic and morphologic characteristics of pure ductal carcinoma in situ (DCIS) lesions depicted on dyna

130 Four of 38 ductal carcinoma in situ (DCIS) lesions diagnosed with 1

131 Certain ductal carcinoma in situ (DCIS) lesions overexpress the

132 at 271 invasive breast cancer tumors and 179 ductal carcinoma in situ (DCIS) lesions were overdiagnos

133 epithelium and occurs in only 3 (16%) of 19 ductal carcinoma in situ (DCIS) lesions, but is present

134 ital mammography depicted significantly more ductal carcinoma in situ (DCIS) lesions, irrespective of

135 52 (61%) lesions: 35 invasive cancers and 17 ductal carcinoma in situ (DCIS) lesions.

136 f key lipogenic genes in clinical samples of ductal carcinoma in situ (DCIS) of breast cancer and fou

137 While the prevalence of ductal carcinoma in situ (DCIS) of the breast has increa

138 Ductal carcinoma in situ (DCIS) of the breast is a non-i

139 The current literature suggests that ductal carcinoma in situ (DCIS) of the breast is infrequ

140 Ductal carcinoma in situ (DCIS) of the breast represents

141 A total of 486 cases of ductal carcinoma in situ (DCIS) of the breast were ident

142 mour in a duct is examined in order to model ductal carcinoma in situ (DCIS) of the breast, the earli

143 s of matched normal ductal/lobular units and ductal carcinoma in situ (DCIS) of the human breast.

144 years or older who were newly diagnosed with ductal carcinoma in situ (DCIS) or breast cancer.

145 ied that semaphorin 7a is a potent driver of ductal carcinoma in situ (DCIS) progression.

146 ic resonance (MR) images are associated with ductal carcinoma in situ (DCIS) recurrence risk after de

147 onserving surgery (BCS) and radiotherapy for ductal carcinoma in situ (DCIS) reduced the absolute occ

148 or recurrence (IBTR) after local excision of ductal carcinoma in situ (DCIS) remains a clinical conce

149 zed SIM2s expression in human primary breast ductal carcinoma in situ (DCIS) samples and found that S

150 and highly and more frequently expressed in ductal carcinoma in situ (DCIS) than in invasive breast

151 invasion and the conversion of human breast ductal carcinoma in situ (DCIS) to infiltrating ductal c

152 ular mechanisms mediating the progression of ductal carcinoma in situ (DCIS) to invasive breast cance

153 The transition from ductal carcinoma in situ (DCIS) to invasive breast cance

154 he processes that control the progression of ductal carcinoma in situ (DCIS) to invasive breast cance

155 The transition from preinvasive ductal carcinoma in situ (DCIS) to invasive breast carci

156 epithelial cells inhibit, the progression of ductal carcinoma in situ (DCIS) to invasive breast carci

157 ilateral breast event (IBE) in patients with ductal carcinoma in situ (DCIS) treated with breast-cons

158 arding the optimal negative margin width for ductal carcinoma in situ (DCIS) treated with breast-cons

159 Some women with unilateral ductal carcinoma in situ (DCIS) undergo contralateral pr

160 oepithelial cells in a subset of preinvasive ductal carcinoma in situ (DCIS) upregulate expression of

161 , whereas they are increased in human breast ductal carcinoma in situ (DCIS) versus normal breast tis

162 lices containing ducts distended with murine ductal carcinoma in situ (DCIS) were prepared for XFM.

163 breast cancer and multicentric tumors, with ductal carcinoma in situ (DCIS) who will undergo mastect

164 H) on a panel of breast tumors, including 10 ductal carcinoma in situ (DCIS), 18 invasive breast carc

165 uding 23 cases of invasive breast cancer, 73 ductal carcinoma in situ (DCIS), 72 with atypical hyperp

166 804 study identified good-risk patients with ductal carcinoma in situ (DCIS), a breast cancer diagnos

167 cer prevention is to reduce the incidence of ductal carcinoma in situ (DCIS), an early stage of breas

168 MR imaging database contained 132 benign, 71 ductal carcinoma in situ (DCIS), and 150 invasive ductal

169 gn ducts, down-regulation in early grades of ductal carcinoma in situ (DCIS), and re-expression in pe

170 cancers detected with mammography alone were ductal carcinoma in situ (DCIS), and the third was DCIS

171 Purpose To compare detection rates of ductal carcinoma in situ (DCIS), classified according to

172 e sequenced exons 9 and 20 of PIK3CA in pure ductal carcinoma in situ (DCIS), DCIS adjacent to invasi

173 use of radiation therapy (RT) in women with ductal carcinoma in situ (DCIS), despite prospective ran

174 to clinical presentation of that cancer, for ductal carcinoma in situ (DCIS), invasive breast cancer,

175 es showed no pathologic abnormality, 21% had ductal carcinoma in situ (DCIS), invasive carcinoma (IC)

176 including one invasive ductal carcinoma, one ductal carcinoma in situ (DCIS), one focus of atypical d

177 Women with ductal carcinoma in situ (DCIS), or stage 0 breast cance

178 the majority of breast cancers diagnosed are ductal carcinoma in situ (DCIS), the most common lesion

179 opose aggressive and non-aggressive forms of ductal carcinoma in situ (DCIS), they cannot be identifi

180 cular alterations driving the progression of ductal carcinoma in situ (DCIS), we compared patients wi

181 Ductal carcinoma in situ (DCIS)--a significant precursor

182 e absence of any residual invasive cancer or ductal carcinoma in situ (DCIS).

183 and proportion of small invasive cancers and ductal carcinoma in situ (DCIS).

184 usual ductal hyperplasia (UDH) or malignant ductal carcinoma in situ (DCIS).

185 ere nine invasive cancers and three cases of ductal carcinoma in situ (DCIS).

186 oninvasive spheroids with characteristics of ductal carcinoma in situ (DCIS).

187 py after breast-conserving surgery (BCS) for ductal carcinoma in situ (DCIS).

188 e adequate treatment for small, grade 1 or 2 ductal carcinoma in situ (DCIS).

189 ven to be more challenging in the setting of ductal carcinoma in situ (DCIS).

190 evels of MMP-26 are strongly up-regulated in ductal carcinoma in situ (DCIS).

191 ers and at higher frequencies in preinvasive ductal carcinoma in situ (DCIS).

192 ) were invasive carcinoma and two (22%) were ductal carcinoma in situ (DCIS).

193 on COX-2 expression in early lesions such as ductal carcinoma in situ (DCIS).

194 xpressed with particularly high frequency in ductal carcinoma in situ (DCIS).

195 usual ductal hyperplasia and low/high grade ductal carcinoma in situ (DCIS).

196 majority of calcifications (68%) were due to ductal carcinoma in situ (DCIS).

197 of early-stage breast lesions, most commonly ductal carcinoma in situ (DCIS).

198 of life (QoL) are scarce among survivors of ductal carcinoma in situ (DCIS).

199 ndard treatment option for the management of ductal carcinoma in situ (DCIS).

200 fen for women with hormone-receptor-positive ductal carcinoma in situ (DCIS).

201 ncer, a benefit has not been demonstrated in ductal carcinoma in situ (DCIS).

202 ed in premalignant breast cancers, including ductal carcinoma in situ (DCIS); however, little is know

203 ssociation between risk factors and incident ductal carcinoma in situ (DCIS; n = 1,453) with that of

204 hocytes in tissue microarray cores from pure ductal carcinoma in situ (DCIS; n = 62), invasive breast

205 bout the quality of treatment for women with ductal carcinoma-in-situ (DCIS) because persistent high

206 The incidence of ductal carcinoma-in-situ (DCIS) of the breast has been i

207 therapy (RT) or mastectomy for patients with ductal carcinoma-in-situ (DCIS) of the breast has not be

208 ation therapy (BCT) for patients treated for ductal carcinoma-in-situ (DCIS) or invasive breast cance

209 67 lesions underwent biopsy, of which 83 (16 ductal carcinoma in situ [DCIS] and 67 invasive cancers)

210 o cancers were found by mammography alone (a ductal carcinoma in situ [DCIS] with microinvasion and a

211 nally shown to be true-positive (23 cases of ductal carcinoma in situ [DCIS], 43 invasive cancers) an

212 Strikingly, the majority (78%) of ductal carcinoma in situ demonstrated markedly or modera

213 Breast cancer or ductal carcinoma in situ developed in 373 patients, with

214 as incidence of all breast cancer (including ductal carcinoma in situ) during a 10 year follow-up per

215 ined invasive ductal carcinoma (IDC) but not ductal carcinoma in situ, fibroadenoma, or normal breast

216 The heterogeneous nature of ductal carcinoma in situ has been emphasised by data for

217 ne of the earliest detectable breast tumors, ductal carcinoma in situ, has become the most rapidly in

218 hitecture in a manner that is reminiscent of ductal carcinoma in situ; however, motile cells do not i

219 ll patient scans, including the detection of ductal carcinoma in situ in 1 case.

220 methods of estimation and the importance of ductal carcinoma in situ in overdiagnosis.

221 rwent mastectomy after cancellation, one had ductal carcinoma in situ in the same quadrant as the MR-

222 rly stages of breast cancer (hyperplasia and ductal carcinoma in situ), in morphogenesis assays G1P3

223 They occur in ductal carcinoma in situ, in breast cancers, and in brea

224 1A promoter hypermethylation was detected in ductal carcinoma in situ, inactivation of RASSF1A may be

225 Imaging of ductal carcinoma in situ, infiltrating cancer, and micro

226 Ductal carcinoma in situ is a common finding in women ha

227 Ductal carcinoma in situ is considered to be a preinvasi

228 Ductal carcinoma in situ is currently managed with excis

229 of mammographic breast screening programmes, ductal carcinoma in situ is diagnosed with increasing fr

230 Mastectomy for localised ductal carcinoma in situ is thought to be an over-treatm

231 cuity of malignant breast lesions, including ductal carcinoma in situ, is significantly improved at c

232 iated, grade 3 invasive ductal carcinoma and ductal carcinoma in situ (largest focus, 3.5 cm).

233 c mutations or deletions of TP53 and PTEN in ductal carcinoma in situ lesions have been implicated in

234 any molecular studies have been performed in ductal carcinoma in situ lesions with the aims of identi

235 ty and the development of estrogen-dependent ductal carcinoma in situ lesions.

236 pression (SAGE) analysis of normal and DCIS (ductal carcinoma in situ) mammary epithelial cells, that

237 ; median diameter, 10 mm), and 43 (25%) were ductal carcinoma in situ (median size, 10 mm).

238 Moreover, further genetic interrogation of ductal carcinoma in situ might lead to a reclassificatio

239 ogic findings of invasive carcinoma (n = 7), ductal carcinoma in situ (n = 1), lobular neoplasia (n =

240 Ductal carcinoma in situ (n = 5) enhanced a mean of 59.6

241 gs included lobular carcinoma in situ (n=2), ductal carcinoma in situ (n=7), papillary carcinoma (n=2

242 Ten women developed 12 breast cancers (ductal carcinoma-in-situ [n = 2], invasive ductal carcin

243 aging depicted 60 additional breast cancers (ductal carcinoma in situ, n = 20; invasive carcinoma, n

244 = 1552) were identified (invasive, n = 1287; ductal carcinoma in situ, n = 270); in five, both kinds

245 s of radiotherapy after sector resection for ductal carcinoma in situ of the breast (DCIS) in patient

246 = 955) compared with patients with residual ductal carcinoma in situ only (n = 309), no invasive res

247 cancer status was defined histologically as ductal carcinoma in situ or invasive cancer.

248 mmon cause of death for women diagnosed with ductal carcinoma in situ or stage I disease and for wome

249 e identified 233,754 patients diagnosed with ductal carcinoma in situ or stage I to III unilateral br

250 ubsequent breast cancers in each subset were ductal carcinoma in situ or stage I.

251 omen aged 20 to 79 years diagnosed as having ductal carcinoma in situ or stages I to III invasive bre

252 1.3, 2.6]; P < .001), invasive cancer versus ductal carcinoma in situ (OR, 1.6 [95% CI: 1.0, 2.4]; P

253 r without a prior diagnosis of breast cancer,ductal carcinoma in situ, or lobular carcinoma in situ.

254 II invasive ductal or lobular breast cancer, ductal carcinoma in situ, or prophylaxis.

255 We surveyed all ductal carcinoma in situ patients and a 20% random sampl

256 , and PI3K catalytic subunit (PIK3CA) in 110 ductal carcinoma in situ, primary tumor, and metastatic

257 amination of archived tissue from women with ductal carcinoma in situ reveals epithelial cells that n

258 t invasive tumor fronts, particularly within ductal carcinoma in situ samples, establishes that EMT-i

259 invasive breast cancer, which revealed that ductal carcinomas in situ show intratumor genetic hetero

260 rs, six were invasive cancers and three were ductal carcinoma in situ stage Tis-T1c.

261 women diagnosed before 50 years of age with ductal carcinoma in situ than with invasive breast cance

262 ramatic improvement in our ability to detect ductal carcinoma in situ, the pathophysiology of this di

263 ompared with total tissue lysates from human ductal carcinoma in situ tissue loaded on basic immobili

264 e examined 296 breast adenocarcinomas and 38 ductal carcinoma in situ tissues that were represented i

265 ng the transition from ductal hyperplasia to ductal carcinoma in situ to adenocarcinoma in widely use

266 urred during the transition from noninvasive ductal carcinoma in situ to invasive breast cancer.

267 tes with increasing disease progression from ductal carcinoma in situ to invasive carcinoma.

268 ogression of breast cancer from premalignant ductal carcinoma in situ to invasive carcinoma.

269 nt chemotaxis in vitro and for conversion of ductal carcinoma in situ to invasive ductal carcinoma in

270 The transition from ductal carcinoma in situ to invasive ductal carcinoma is

271 erative index Ki67) increased from normal to ductal carcinoma in situ to invasive, whereas Syk in sit

272 d in healthy tissue but already prominent in ductal carcinoma in situ, together with ECM and cell-cel

273 profile established for the normal breast to ductal carcinoma in situ transition was largely maintain

274 therapy can be recommended for patients with ductal carcinoma in situ treated by complete local excis

275 Postmenopausal women with hormone-positive ductal carcinoma in situ treated by lumpectomy with clea

276 Postmenopausal women with hormone-positive ductal carcinoma in situ treated by lumpectomy with clea

277 1184 patients with low-risk invasive and ductal carcinoma in situ treated with breast-conserving

278 UK/ANZ DCIS (UK, Australia, and New Zealand ductal carcinoma in situ) trial suggested that radiother

279 ersus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radi

280 Of these, 64.7% (11 of 17) were ductal carcinoma in situ versus 6.7% (two of 30) of canc

281 stology, for identifying invasive cancer and ductal carcinoma in situ versus benign breast tissue.

282 duced by tamoxifen but recurrence of overall ductal carcinoma in situ was decreased (hazard ratio 0.6

283 The rate of screening-detected ductal carcinoma in situ was higher (P = .019) while the

284 The incidence of ductal carcinoma in situ was higher in bisphosphonate us

285 The duct in one patient with ductal carcinoma in situ was weakly enhancing.

286 Penetrance of ductal carcinomas in situ was also decreased.

287 in the first or second specimen; one cancer (ductal carcinoma in situ) was diagnosed with cells conta

288 rate (including invasive breast cancers and ductal carcinomas in situ) was not significant (4.15 cas

289 In cellular models of breast ductal carcinoma in situ, we reveal a link between filop

290 f 18437 women with invasive breast cancer or ductal carcinoma in situ were enrolled as cases and matc

291 e, missing stage or treatment data, and with ductal carcinoma in situ were excluded, leaving 3729 pat

292 ts A total of 45 cancers (33 invasive and 12 ductal carcinomas in situ) were diagnosed, 43 were seen

293 size T3/T4), inflammatory breast cancer, or ductal carcinoma in situ (when breast-conserving surgery

294 rial of breast excision alone for women with ductal carcinoma in situ, which was stopped early becaus

295 breast cancer and multicentric tumors, with ductal carcinoma in situ, who will undergo mastectomy, w

296 sive breast cancer (IBC) and 50,000 cases of ductal carcinoma in situ will be diagnosed and 40,000 wo

297 hyperplasia or lobular carcinoma in situ; or ductal carcinoma in situ with mastectomy.

298 2963 were diagnosed with invasive cancer or ductal carcinoma in situ within 12 months of screening.

299 Diagnosis of invasive cancer or ductal carcinoma in situ within 24 months of screening e

300 re diagnosed with breast cancer (invasive or ductal carcinoma in situ) within 12 months of screening